1. Home
  2. ETV vs PHVS Comparison

ETV vs PHVS Comparison

Compare ETV & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

ETV

Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

HOLD

Current Price

$14.40

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$26.88

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETV
PHVS
Founded
2005
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ETV
PHVS
Price
$14.40
$26.88
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$39.44
AVG Volume (30 Days)
252.5K
528.8K
Earning Date
01-01-0001
11-12-2025
Dividend Yield
8.75%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.05
$11.51
52 Week High
$13.50
$29.80

Technical Indicators

Market Signals
Indicator
ETV
PHVS
Relative Strength Index (RSI) 56.11 54.78
Support Level $14.26 $23.80
Resistance Level $14.61 $29.80
Average True Range (ATR) 0.20 2.25
MACD 0.03 0.19
Stochastic Oscillator 78.65 53.48

Price Performance

Historical Comparison
ETV
PHVS

About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: